Abstract:One characteristic feature of Alzheimer's disease (AD) neuropathology is the progressive generation, aggregation and deposition of the 42 amino acid amyloid beta (Aβ42) peptide, and other related amyloidogenic molecules, into dense clumps of insoluble, pro-inflammatory senile plaque cores in the extracellular space of the brain. It is not generally appreciated that the Aβ42 peptide, derived via tandem beta-gamma secretase cleavage of the larger ~770 amino acid transmembrane beta-amyloid precursor protein (βAPP) is one of the “stickiest” peptides known, due in part to its high content of lipophillic and hydrophobic peptide domains (21.4% valine-isoleucine; Mager, 1998; Watson et al., 2005). Aβ42 peptide monomers have tremendously high potential for relatively rapid self-aggregation into Aβ42 peptide dimers and higher order fibrillar structures via long-range, non-covalent hydrophobic forces that over time promote β-pleated sheet conformations (Mager, 1998; Watson et al., 2005; Boutajangout and Wisniewski, 2013; Chang et al., 2013). There is abundant evidence that under normal, homeostatic conditions, Aβ42 peptide monomers and perhaps other higher order Aβ42 peptides are effectively “cleared” from the brain's extracellular medium by highly active and efficient innate-immune surveillance and phagocytic systems that limit excessive Aβ42 peptide dimerization, accumulation and further self-aggregation into pathological senile plaque lesions. Recently described, one of the key phagocytosis sensor-receptors responsible for Aβ42 peptide clearance from the human central nervous system (CNS) is very likely the triggering receptor expressed in myeloid/microglial cells 2 (TREM2) enriched in myeloid cells and microglial cells of the CNS (Benitez et al., 2013; Forabosco et al., 2013; Gonzalez Murcia et al., 2013; Guerreiro et al., 2013; Neumann and Daly, 2013; Zhao et al., 2013; Jones et al., 2014; Figure Figure1).1). This short paper is an update on some very recent observations on TREM2 neurobiology, on newly discovered roles for miRNA-34a-mediated signaling in human degenerative disease, including miRNA-34a-mediated effects on TREM2 expression, and how dysfunctional TREM2 signaling may contribute to amyloidogenesis in AD and in related progressive, inflammatory neurodegenerative diseases of the human CNS.

Microglia Process α‐Synuclein Fibrils and Enhance their Pathogenicity in a TREM2‐Dependent Manner

Microglia Gravitate toward Amyloid Plaques Surrounded by Externalized Phosphatidylserine via TREM2

Intracellular trafficking of TREM2 is regulated by presenilin 1

Elevating Microglia TREM2 Reduces Amyloid Seeding and Suppresses Disease-Associated Microglia

TREM2 drives microglia response to amyloid-β via SYK-dependent and -independent pathways

TREM1 Facilitates Microglial Phagocytosis of Amyloid Beta

TREM2 Deficiency Aggravates Α‐synuclein–induced Neurodegeneration and Neuroinflammation in Parkinson's Disease Models

Microglia, Trem2, and Neurodegeneration

Activated microglia facilitate the transmission of α-synuclein in Parkinson's disease

Reactive microglia enhance the transmission of exosomal α-synuclein via toll-like receptor 2

Parkinson's disease-derived α-synuclein assemblies combined with chronic-type inflammatory cues promote a neurotoxic microglial phenotype

Expression of the phagocytosis-essential protein TREM2 is down-regulated by an aluminum-induced miRNA-34a in a murine microglial cell line.

α‐synuclein suppresses microglial autophagy and promotes neurodegeneration in a mouse model of Parkinson’s disease

TREM2 modulates microglia phenotypes in the neuroinflammation of Parkinson's disease

Over-Expressed Pathogenic Mirnas in Alzheimer’s Disease (AD) and Prion Disease (prd) Drive Deficits in TREM2-Mediated Aβ42 Peptide Clearance

Deficits in the Mirna-34A-regulated Endogenous TREM2 Phagocytosis Sensor-Receptor in Alzheimer's Disease (AD); an Update.

TREM2 is a Receptor for Β-Amyloid That Mediates Microglial Function

O4‐02‐01: SOLUBLE TREM2 MODULATES MICROGLIAL FUNCTION AND PROTECTS AGAINST AMYLOID PATHOLOGY

alpha-synuclein suppresses microglial autophagy and promotes neurodegeneration in a mouse model of Parkinson's disease

Up-regulation of TREM2 accelerates the reduction of amyloid deposits and promotes neuronal regeneration in the hippocampus of amyloid beta1-42 injected mice

Aggregated -synuclein activates microglia: a process leading to disease progression in Parkinson's disease